M
-
F
,
8
am -
6
pm ET

Resources for You and Your Family

As part of our ongoing support, we have provided some helpful resources about Alnylam Assist® and treatment with OXLUMOTM (lumasiran). In addition, we’ve included some organizations that provide community support and educational materials for those affected by primary hyperoxaluria type 1 (PH1).

Your Team at a Glance

Alnylam Assist® Case Managers

After you begin treatment and enroll in Alnylam Assist®, your dedicated Case Manager, a Patient Education Liaison (PEL), and the Alnylam Assist® team will provide ongoing one-on-one support and education in 3 key areas:

Understanding Benefits

Financial Options

Disease and Treatment

Alnylam Assist® - Downloadable PDF

Alnylam Assist® Brochure

Download

Alnylam Assist® - FAQ Icon

Alnylam Assist® FAQs

Visit FAQs Page

OXLUMO™ Resources

Explore the resources below to learn about treatment with OXLUMO.

Alnylam Assist® - Downloadable PDF

OXLUMO™ (lumasiran) Brochure

This brochure helps educate and inform you and your loved ones about PH1, describes how PH1 affects your body, and shows results from an OXLUMO clinical study.

Download PDF

Insurance Resources

Alnylam Assist® provides insurance benefit guidance and resources
to help support patients throughout treatment.

00%
of patients enrolled in Alnylam Assist® have confirmed coverage for OXLUMO
00%
of patients with zero cost-share for OXLUMO
00%
U.S. lives with confirmed access to OXLUMO across commercial, Medicare, Medicaid, and other government payer categories
Alnylam Assist® - Downloadable PDF

Explanation of Benefits (EOB)

This sheet outlines insurance company EOBs, what information they contain, and how to better understand them.

Download PDF

Alnylam Assist® - Downloadable PDF

Glossary of Insurance Terms

A handy reference glossary to help educate patients and caregivers about common insurance terminology.

Download PDF

Alnylam Assist® - Downloadable PDF

Young Adult Transitions Brochure

Young adult patients with rare diseases who are transitioning to their own insurance have important decisions to make. This brochure covers the most important aspects of changing insurance plans.

Download PDF

Caregiver Resources

Caregivers of people with PH1 can play a vital role in helping successfully support their loved ones throughout treatment. Caregiver resources are designed to help these important individuals.

Alnylam Assist® - Downloadable PDF

Alnylam Assist® Caregiver Brochure

This brochure was designed to support caregivers of patients with rare diseases by offering best practices and tips on how to talk to the healthcare team, dealing with young children, and self-care.

Download PDF

Disease and Advocacy Resources

Oxalosis and Hyperoxaluria Foundation Logo

Oxalosis & Hyperoxaluria Foundation (OHF)

The OHF is dedicated to finding treatments and a cure for all forms of hyperoxaluria, and supports thousands of healthcare professionals, patients, and their families in their fight against this disease.

www.ohf.org

National Kidney Foundation

The National Kidney Foundation is a lifeline for people with kidney disease, enhancing lives through education.

www.kidney.org

National Institute of Diabetes and Digestive and Kidney Diseases

The National Institute of Diabetes and Digestive and Kidney Diseases conducts and supports research on the most common, costly, and chronic conditions.

www.niddk.nih.gov

National Center for Advancing Translational Sciences

The National Center for Advancing Translational Sciences turns observations into approaches and technologies that can help deliver treatments to more people more quickly.

www.ncats.nih.gov

National Organization for Rare Disorders Logo

National Organization for Rare Disorders

The National Organization for Rare Disorders offers educational videos and interactive webinars along with a variety of additional resources.

www.rarediseases.org

Global Genes Logo

Global Genes

Global Genes is your ally in the fight against rare disease. Global Genes provides helpful resources while sponsoring local and global events to help connect, empower, and inspire the rare disease community.

www.globalgenes.org

For Caregivers

Caregiver Action Network (CAN)

The Caregiver Action Network is the nation's leading family caregiver organization working to improve quality of life for the more than 90 million Americans who care for their loved ones.

www.caregiveraction.org

National Alliance for Caregiving (NAC)

The National Alliance for Caregiving is a non-profit coalition dedicated to improving quality of life for friend and family caregivers and those in their care, by advancing research, advocacy, and innovation.

www.caregiving.org

How do I get started with Alnylam Assist®?

To get started, you must be prescribed OXLUMO and fill out the Start Form with your doctor. Once the form is completed and you’ve signed it, your doctor can submit the form online or print it out and fax it to Alnylam Assist®. Find out how to get started ›

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

Alnylam Assist® get started icon

See How to Get Started

Once you and your doctor decide to begin treatment with OXLUMO, we'll work with your healthcare team to start the process.

How to Get Started

Alnylam Assist® Case Manager Shontae

Call Shontae

1-833-256-2748

Monday - Friday, 8am - 6pm ET

Alylam Separator Triangles

IMPORTANT SAFETY INFORMATION

The most common side effect of OXLUMOTM (lumasiran) is injection site reaction (redness, pain, itching, and swelling at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

WHAT IS OXLUMO?

OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.